Liraglutide
An older but well-proven GLP-1 medication taken as a daily injection. Sold as Victoza for diabetes and Saxenda for weight loss. Still widely used in India.
Liraglutide was one of the first GLP-1 medications and has the longest safety track record. It requires daily injections (unlike weekly semaglutide) but is well-studied, widely available in India, and effective for both blood sugar control and moderate weight loss.
Good for you if: You have type 2 diabetes or obesity and prefer (or your doctor recommends) a daily GLP-1 injection, or you want a medication with the longest safety track record in this class.
Dive deeper into the researchCommon side effects
- Nausea in 30–40% of users — usually milder than semaglutide
- Daily injections can be less convenient than weekly alternatives
- Same serious risk profile as other GLP-1 drugs (pancreatitis, thyroid)
What does liraglutide do?
Like semaglutide, liraglutide mimics GLP-1 — the gut hormone that controls appetite and insulin. The main difference is that liraglutide has a shorter half-life (~13 hours vs ~7 days for semaglutide), so you need to inject it every day instead of once a week.
It produces moderate weight loss — about 5–8% of body weight at the weight-management dose (3 mg/day) — and significant blood sugar improvement. It also has proven cardiovascular benefits: the LEADER trial showed a 13% reduction in major cardiovascular events.
Who is it for?
- Type 2 diabetes — as Victoza (up to 1.8 mg/day)
- Weight management — as Saxenda (up to 3.0 mg/day)
- People who prefer daily dosing or whose doctor recommends starting with a well-established GLP-1
How it's taken
Start at 0.6 mg/day for 1 week, then increase by 0.6 mg each week until you reach the target dose. Victoza target: 1.2–1.8 mg/day. Saxenda target: 3.0 mg/day.
Inject once daily at any time, with or without food. Same time each day is recommended for consistency.
Availability in India
Liraglutide is available in India as Victoza (Novo Nordisk) for diabetes. Saxenda (weight-management dose) has more limited availability. Cost is approximately ₹5,000–₹12,000 per month. It's one of the most established GLP-1 medications in India.
Track your GLP-1 biomarkers with eterni
HbA1c, fasting insulin, body composition, and more — monitored over time so you can see if your protocol is working.
Get early accessFrequently Asked Questions
How is liraglutide different from semaglutide?
Both are GLP-1 receptor agonists, but semaglutide is taken weekly and produces more weight loss (15–17% vs 5–8%). Liraglutide requires daily injection but has a longer safety track record. Semaglutide has largely replaced liraglutide for new prescriptions.
Does liraglutide cause the same side effects as Ozempic?
Yes, the side-effect profile is similar — nausea, vomiting, diarrhoea, and constipation are most common. The rates tend to be slightly lower with liraglutide. Serious risks (pancreatitis, thyroid) are the same across all GLP-1 drugs.
Can liraglutide be used for weight loss in India?
Victoza (up to 1.8 mg/day) is approved for diabetes. Saxenda (3.0 mg/day) is the weight-loss formulation but has limited availability in India. Some doctors prescribe Victoza off-label for weight management.
How long has liraglutide been available?
Liraglutide was first approved in 2010, making it one of the longest-studied GLP-1 medications. It has over 15 years of real-world safety data, including the landmark LEADER cardiovascular outcomes trial.
How it works in your body
Liraglutide binds to GLP-1 receptors in the brain, pancreas, and gut — same mechanism as semaglutide. Its shorter half-life (~13 hours) means effects are less sustained, which is why daily dosing is needed. The 97% amino acid similarity to human GLP-1 gives it good receptor affinity.
Clinical trial data
- LEADER: 13% reduction in major cardiovascular events over 3.8 years in type 2 diabetes
- SCALE: 8% weight loss at 3.0 mg/day vs 2.6% placebo over 56 weeks
- HbA1c reduction: 1.0–1.5% across diabetes trials
- Safety: Longest post-marketing safety data of any GLP-1 drug
Biomarker monitoring
Same as other GLP-1 drugs: HbA1c, fasting glucose, fasting insulin, lipid panel, liver enzymes, kidney function, and thyroid panel.
Side effects & safety
Similar to semaglutide but generally milder due to the lower peak effect of daily dosing.
- Nausea — 30–40% (often milder than semaglutide)
- Diarrhoea — 10–20%
- Constipation — 8–15%
- Headache — reported in some users during early titration
- Injection site reactions — mild redness or bruising
- Pancreatitis — rare but serious
- Gallbladder disease with rapid weight loss
- Thyroid C-cell tumours (boxed warning) — contraindicated with MTC/MEN 2 history
Know what's working. Know what's not.
eterni connects your lab results, medications, and retests — so you can see the trajectory, not just a snapshot.
Join the waitlist